These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 22443113)

  • 1. The emerging role of ALK inhibitors in the treatment of advanced non-small cell lung cancer.
    Galetta D; Rossi A; Pisconti S; Colucci G
    Expert Opin Ther Targets; 2012 Apr; 16 Suppl 2():S45-54. PubMed ID: 22443113
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Crizotinib: a new treatment option for ALK-positive non-small cell lung cancer.
    O'Bryant CL; Wenger SD; Kim M; Thompson LA
    Ann Pharmacother; 2013 Feb; 47(2):189-97. PubMed ID: 23386065
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Crizotinib, a small-molecule dual inhibitor of the c-Met and ALK receptor tyrosine kinases.
    Rodig SJ; Shapiro GI
    Curr Opin Investig Drugs; 2010 Dec; 11(12):1477-90. PubMed ID: 21154129
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Crizotinib in the treatment of non-small-cell lung cancer.
    Forde PM; Rudin CM
    Expert Opin Pharmacother; 2012 Jun; 13(8):1195-201. PubMed ID: 22594847
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting anaplastic lymphoma kinase in lung cancer.
    Shaw AT; Solomon B
    Clin Cancer Res; 2011 Apr; 17(8):2081-6. PubMed ID: 21288922
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PROFILing non-small-cell lung cancer patients for treatment with crizotinib according to anaplastic lymphoma kinase abnormalities: translating science into medicine.
    Pilotto S; Peretti U; Novello S; Rossi G; Milella M; Giaj Levra M; Ciuffreda L; Massari F; Brunelli M; Tortora G; Bria E
    Expert Opin Pharmacother; 2013 Apr; 14(5):597-608. PubMed ID: 23472711
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibitors of the anaplastic lymphoma kinase.
    Mologni L
    Expert Opin Investig Drugs; 2012 Jul; 21(7):985-94. PubMed ID: 22612599
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The preclinical profile of crizotinib for the treatment of non-small-cell lung cancer and other neoplastic disorders.
    Roskoski R
    Expert Opin Drug Discov; 2013 Sep; 8(9):1165-79. PubMed ID: 23805942
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of anaplastic lymphoma kinase inhibitors in the treatment of advanced nonsmall cell lung cancer.
    D'Arcangelo M; Wynes MW; Hirsch FR
    Curr Opin Oncol; 2013 Mar; 25(2):121-9. PubMed ID: 23385859
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of ALK-positive non-small cell lung cancer.
    Bang YJ
    Arch Pathol Lab Med; 2012 Oct; 136(10):1201-4. PubMed ID: 23020724
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Virtual screening and further development of novel ALK inhibitors.
    Okamoto M; Kojima H; Saito N; Okabe T; Masuda Y; Furuya T; Nagano T
    Bioorg Med Chem; 2011 May; 19(10):3086-95. PubMed ID: 21515061
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ALK inhibitors and advanced non-small cell lung cancer (review).
    Rossi A; Maione P; Sacco PC; Sgambato A; Casaluce F; Ferrara ML; Palazzolo G; Ciardiello F; Gridelli C
    Int J Oncol; 2014 Aug; 45(2):499-508. PubMed ID: 24889366
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current status of targeted therapy for anaplastic lymphoma kinase-rearranged non-small cell lung cancer.
    Solomon B; Wilner KD; Shaw AT
    Clin Pharmacol Ther; 2014 Jan; 95(1):15-23. PubMed ID: 24091716
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Favorable response to crizotinib in three patients with echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase fusion-type oncogene-positive non-small cell lung cancer.
    Kijima T; Takeuchi K; Tetsumoto S; Shimada K; Takahashi R; Hirata H; Nagatomo I; Hoshino S; Takeda Y; Kida H; Goya S; Tachibana I; Kawase I
    Cancer Sci; 2011 Aug; 102(8):1602-4. PubMed ID: 21767331
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ALK translocation and crizotinib in non-small cell lung cancer: an evolving paradigm in oncology drug development.
    Scagliotti G; Stahel RA; Rosell R; Thatcher N; Soria JC
    Eur J Cancer; 2012 May; 48(7):961-73. PubMed ID: 22397764
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Hsp90 inhibitor IPI-504 rapidly lowers EML4-ALK levels and induces tumor regression in ALK-driven NSCLC models.
    Normant E; Paez G; West KA; Lim AR; Slocum KL; Tunkey C; McDougall J; Wylie AA; Robison K; Caliri K; Palombella VJ; Fritz CC
    Oncogene; 2011 Jun; 30(22):2581-6. PubMed ID: 21258415
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting ALK in patients with advanced non small cell lung cancer: biology, diagnostic and therapeutic options.
    Lazzari C; Spitaleri G; Catania C; Barberis M; Noberasco C; Santarpia M; Delmonte A; Toffalorio F; Conforti F; De Pas TM
    Crit Rev Oncol Hematol; 2014 Mar; 89(3):358-65. PubMed ID: 24156959
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alectinib for the treatment of ALK-positive stage IV non-small cell lung cancer.
    Wong KM; Noonan S; O'Bryant C; Jimeno A
    Drugs Today (Barc); 2015 Mar; 51(3):161-70. PubMed ID: 25876560
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Crizotinib in the treatment of non--small-cell lung cancer.
    Rothschild SI; Gautschi O
    Clin Lung Cancer; 2013 Sep; 14(5):473-80. PubMed ID: 23790969
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activation of HER family signaling as a mechanism of acquired resistance to ALK inhibitors in EML4-ALK-positive non-small cell lung cancer.
    Tanizaki J; Okamoto I; Okabe T; Sakai K; Tanaka K; Hayashi H; Kaneda H; Takezawa K; Kuwata K; Yamaguchi H; Hatashita E; Nishio K; Nakagawa K
    Clin Cancer Res; 2012 Nov; 18(22):6219-26. PubMed ID: 22843788
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.